Premium
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial Sub-study will investigate effects of MST-188 on tissue oxygenation in sickle cell disease patients experiencing a vaso-occlusive...
Mast Therapeutics Announces New Data Supporting MST-188 In Sickle Cell Disease MST-188 decreased a marker of inflammation and red blood cell aggregation (50% reduction relative to control) Data...
Mast Therapeutics Signs Definitive Agreement To Acquire Aires Pharmaceuticals, Inc. - All-stock transaction - Conference call to discuss pending acquisition today at 8:30am Eastern Time PR...
Mast Therapeutics To Present At The Rodman & Renshaw 15th Annual Healthcare Conference On September 10 PR Newswire SAN DIEGO, Sept. 3, 2013 SAN DIEGO, Sept. 3, 2013 /PRNewswire/ -- Mast...
ADVENTRX Completes Name Change To "Mast Therapeutics, Inc."; New Ticker Symbol: "MSTX" PR Newswire SAN DIEGO, March 11, 2013 SAN DIEGO, March 11, 2013 /PRNewswire/ -- ADVENTRX...
ADVENTRX Announces Corporate Name Change To "Mast Therapeutics, Inc."; Ticker Symbol Change To "MSTX" Name and ticker symbol changes effective March 11, 2013 PR Newswire SAN...
Adventrx To Develop ANX-188 For Complications Of Arterial Disease - Seeking orphan drug designation in acute limb ischemia (ALI) - Phase 2 clinical proof-of-concept in ALI planned for late...
ADVENTRX Reviews Data Supporting Development Of ANX-188 In New Indications - Platform includes over 100 pharmacology studies, 15 clinical studies and 2,500 patient exposures - ANX-188 phase...
ADVENTRX To Present At The Cowen And Company 33rd Annual Health Care Conference On March 4 PR Newswire SAN DIEGO, Feb. 25, 2013 SAN DIEGO, Feb. 25, 2013 /PRNewswire/ -- ADVENTRX Pharmaceuticals...
ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188 PR Newswire SAN DIEGO, Feb. 11, 2013 SAN DIEGO, Feb. 11, 2013 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Symbole | Prix | Vol. |
|---|---|---|
| KULRKULR Technology Group Inc | US$ 2,07 (43,75%) | 136,15M |
| TSLZT Rex 2X Inverse Tesla Daily Target ETF | US$ 2,25 (16,88%) | 127,98M |
| SPYSPDR S&P 500 | US$ 586,28 (-2,98%) | 107,6M |
| SOXLDirexion Daily Semiconductor Bull 3X Shares | US$ 27,83 (-10,60%) | 102,52M |
| HYGiShares iBoxx Dollar High Yield Corporate Bond | US$ 78,17 (-1,54%) | 81,12M |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
